Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice-Reference-Cited by-同舟云学术

Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice

Published:2018-05 Issue: Volume:379 Page:228-238
ISSN:0306-4522
Container-title:Neuroscience
language:en
Short-container-title:Neuroscience

Author:

Buonvicino Daniela,Felici Roberta,Ranieri Giuseppe,Caramelli Riccardo,Lapucci Andrea,Cavone Leonardo,Muzzi Mirko,Di Pietro Lorena,Bernardini Camilla,Zwergel Clemens,Valente Sergio,Mai Antonello,Chiarugi Alberto

Funder

ARISLA

Publisher

Elsevier BV

Subject

General Neuroscience

Reference49 articles.

1. Early signs of motoneuron vulnerability in a disease model system: Characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice;Avossa;Neuroscience,2006

2. High yield extraction of pure spinal motor neurons, astrocytes and microglia from single embryo and adult mouse spinal cord;Beaudet;Sci Rep,2015

3. Differential expression of HDAC and HAT genes in atrophying skeletal muscle;Beharry;Muscle Nerve,2015

4. ALS and FTD: an epigenetic perspective;Belzil;Acta Neuropathol,2016

5. Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4;Bongers;Am J Physiol Endocrinol Metab,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of histone deacetylases and their inhibitors in neurological diseases;Pharmacological Research;2024-09

2. Restoration of epigenetic impairment in the skeletal muscle and chronic inflammation resolution as a therapeutic approach in sarcopenia;Ageing Research Reviews;2024-04

3. Genomic and transcriptomic advances in amyotrophic lateral sclerosis;Ageing Research Reviews;2023-12

4. Sodium butyrate does not protect spinal motor neurons from AMPA-induced excitotoxic degeneration in vivo;Disease Models & Mechanisms;2023-10-01

5. Synergistic association of resveratrol and histone deacetylase inhibitors as treatment in amyotrophic lateral sclerosis;Frontiers in Pharmacology;2022-10-21